RT Journal Article SR Electronic T1 Nestin is expressed in basal-like and triple negative breast cancers JF Journal of Clinical Pathology JO J Clin Pathol FD BMJ Publishing Group Ltd and Association of Clinical Pathologists SP 1045 OP 1050 DO 10.1136/jcp.2008.058750 VO 61 IS 9 A1 S Parry A1 K Savage A1 C MarchiĆ² A1 J S Reis-Filho YR 2008 UL http://jcp.bmj.com/content/61/9/1045.abstract AB Aims: To analyse the distribution of nestin expression in different breast tumours and to determine the prognostic impact of nestin expression.Methods: Nestin expression was immunohistochemically analysed in a cohort of 245 invasive breast cancer patients treated with therapeutic surgery followed by anthracycline-based chemotherapy using a semi-quantitative scoring system.Results: Nestin was exclusively expressed in grade III breast carcinoma and preferentially expressed in basal-like and triple negative cancers. Nestin-positive tumours displayed high proliferation rates and p53 nuclear expression. Lymph-node positive patients with nestin-positive cancers had a shorter breast cancer specific survival; however nestin was not an independent prognostic factor on multivariate analysis.Conclusions: Nestin expression is preferentially found in basal-like and triple negative breast carcinomas. Further studies are warranted to define the biological role played by nestin in these subgroups of breast cancers.